Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Carob extract supplement tested as potential prediabetes aid

NCT ID NCT07420998

Disease control Sponsor: Universidad Católica San Antonio de Murcia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a liquid supplement made from carob extract can improve blood sugar control in people with prediabetes. Thirty adults with prediabetes will take either the carob supplement or a placebo before meals for a period of time. Researchers will measure changes in blood sugar and insulin levels to see if the supplement helps manage carbohydrate metabolism.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carob extract (NUTIFOOD)
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage prediabetes and reduce the risk of developing type 2 diabetes.
What could go wrong
This is a very small, early-stage trial with only 30 people. The supplement may show no benefit over placebo, and results may not apply to everyone with prediabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects of both sexes aged 18-65 years. * Diagnosis of glucose intolerance according to the American Diabetes Association (at least one of the following criteria): * Impaired fasting glucose (100-125 mg/dl) * Impaired glucose tolerance (oral glucose tolerance test with 2-hour plasma glucose between 140-199 mg/dl) * Glycated hemoglobin between 5.7% and 6.4% * Body mass index between 20-35 kg/m². * Stable dietary habits: no weight gain or loss greater than 5 kg in the last ten weeks. * Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements. Exclusion Criteria: * Use of medications that may interfere with glucose metabolism. * Subjects with a history of any type of hepatic or renal disease. * Alcohol consumption greater than 20 g/day. * History of allergic hypersensitivity or poor tolerance to any component of the study products. * Participation in another clinical trial within the three months prior to the study. * Lack of willingness or inability to comply with clinical trial procedures. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prediabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prediabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCAM HiTech, Sport & Health Innovation Hub

    RECRUITING

    Murcia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.